These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 10550309

  • 1. Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells.
    Christa L, Simon MT, Brezault-Bonnet C, Bonte E, Carnot F, Zylberberg H, Franco D, Capron F, Roskams T, Bréchot C.
    Am J Pathol; 1999 Nov; 155(5):1525-33. PubMed ID: 10550309
    [Abstract] [Full Text] [Related]

  • 2. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K, Sasaki M, Fujii T, Harada K, Zen Y, Sato Y, Sawada S, Minato H, Matsui O, Nakanuma Y.
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [Abstract] [Full Text] [Related]

  • 3. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
    Zimmerman RL, Fogt F, Burke M, Murakata LA.
    Oncol Rep; 2002 Sep; 9(4):689-92. PubMed ID: 12066193
    [Abstract] [Full Text] [Related]

  • 4. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N, Watanabe T, Izumisato Y, Suzuki Y, Masaki T, Mori T, Sugiyama M, Fusco A, Atomi Y.
    J Gastroenterol; 2003 Sep; 38(12):1144-9. PubMed ID: 14714251
    [Abstract] [Full Text] [Related]

  • 5. HIP/PAP is an adhesive protein expressed in hepatocarcinoma, normal Paneth, and pancreatic cells.
    Christa L, Carnot F, Simon MT, Levavasseur F, Stinnakre MG, Lasserre C, Thepot D, Clement B, Devinoy E, Brechot C.
    Am J Physiol; 1996 Dec; 271(6 Pt 1):G993-1002. PubMed ID: 8997243
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
    Ikeda H, Sato Y, Yoneda N, Harada K, Sasaki M, Kitamura S, Sudo Y, Ooi A, Nakanuma Y.
    Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
    [Abstract] [Full Text] [Related]

  • 9. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, Kondo R, Nomura Y, Koura K, Ueda K, Sanada S, Naito Y, Yamaguchi R, Yano H.
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [Abstract] [Full Text] [Related]

  • 10. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
    Aishima S, Asayama Y, Taguchi K, Sugimachi K, Shirabe K, Shimada M, Sugimachi K, Tsuneyoshi M.
    Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
    Batmunkh E, Tátrai P, Szabó E, Lódi C, Holczbauer A, Páska C, Kupcsulik P, Kiss A, Schaff Z, Kovalszky I.
    Hum Pathol; 2007 Oct; 38(10):1508-15. PubMed ID: 17640714
    [Abstract] [Full Text] [Related]

  • 13. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
    Morita D, Kagata Y, Ogata S, Tsuda H, Hatsuse K, Mochizuki H, Matsubara O.
    Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
    [Abstract] [Full Text] [Related]

  • 14. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS, Ramalho LN, Della Porta L, Zucoloto S.
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [Abstract] [Full Text] [Related]

  • 15. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E, Wilkens L, Banz V, Osterreicher CH, Weimann R, Eisele S, Keogh A, Stroka D, Zimmermann A, Stickel F.
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synchronous hepatocellular carcinoma and cholangiocarcinoma arising in two different dysplastic nodules.
    Kwon Y, Lee SK, Kim JS, Ro JY, Yu E.
    Mod Pathol; 2002 Oct; 15(10):1096-101. PubMed ID: 12379757
    [Abstract] [Full Text] [Related]

  • 18. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.
    Tanaka S, Hirohashi K, Uenishi T, Yamamoto T, Hamba H, Kubo S, Tanaka H, Shuto T, Ogawa M, Kinoshita H.
    Hepatogastroenterology; 2004 Oct; 51(57):839-41. PubMed ID: 15143930
    [Abstract] [Full Text] [Related]

  • 19. Synemin expression is widespread in liver fibrosis and is induced in proliferating and malignant biliary epithelial cells.
    Schmitt-Graeff A, Jing R, Nitschke R, Desmoulière A, Skalli O.
    Hum Pathol; 2006 Sep; 37(9):1200-10. PubMed ID: 16938526
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
    Okuda H, Shiratori K, Yamamoto M, Takasaki K, Nakano M.
    J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.